Marrinan SL, et al. - The effect of camicinal (GSK962040), a gastroprokinetic, was evaluated on the absorption of L-dopa and symptoms of Parkinson's disease (PD). The researchers found improvement in PD symptom with camicinal in parallel with the more rapid absorption of L-dopa. This outcome provided evidence of an improvement of the motor response to L-dopa in people with PD treated with camicinal 50 mg once-daily compared with placebo, which would require further evaluation.